A phase I study of active immunotherapy with CAP-1 (6D) and CMVpp65 peptide-pulsed, autologous dendritic cells produced in the aastromreplicell cell production system in patients with stage IV CEA expressing malignancies.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs CAP1-6D peptide vaccine (Primary) ; ITI 1000 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 08 Sep 2014 Biomarkers information updated
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 20 Sep 2006 Status changed from recruiting to in progress.